Effects of structural modifications on the intestinal permeability of angiotensin II receptor antagonists and the correlation of in vitro, in situ, and in vivo absorption

Pharmaceutical Research

Volumn 13, Issue 2, 1996, Pages 227-233

  Ribadeneira, Maria D ^a   Aungst, Bruce J ^a   Eyermann, Charles J ^a   Huang, Shiew Mei ^a  

^a DUPONT COMPANY   (United States)

Author keywords

Bioavailability; Caco 2 cells; Hydrogen bonding; Intestinal absorption; Lipophilicity; Solvation energy

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 4 PENTAFLUOROETHYL 2 PROPYL 1 [[2' (1H TETRAZOL 5 YL)BIPHENYL 4 YL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CYCLO(DEXTRO 2 AMINOBUTYRYL 2 N METHYLARGINYLGLYCYLASPARTYL 3 AMINOMETHYLBENZOIC ACID) METHANESULFONATE; DMP 811; DUP 167; LINOPIRDINE; LOSARTAN; PROPRANOLOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOAVAILABILITY; COLON ADENOCARCINOMA; DRUG ABSORPTION; ENERGY; FEMALE; HUMAN; HUMAN CELL; HYDROGEN BOND; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; LIPOPHILICITY; NONHUMAN; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; BIPHENYL COMPOUNDS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CHEMISTRY, PHYSICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; HYDROGEN-ION CONCENTRATION; IMIDAZOLES; INDOLES; INTESTINAL ABSORPTION; LOSARTAN; MALE; MESYLATES; OCTANOLS; PEPTIDES, CYCLIC; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANGIOTENSIN; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES;

EID: 0029865476     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016086930019     Document Type: Article

References (28)

1. G. L. Amidon, P. J. Sinko, and D. Fleisher. Estimating human oral fractional dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm. Res. 5:651-654 (1988).
2. P. Artursson and J. Karlsson. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Comm. 175:880-885 (1991).
3. P. Artursson. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. 79:476-482 (1990).
4. D. C. Kim, P. S. Burton, and R. T. Borchardt. A correlation between the permeability characteristics of a series of peptides using an in vitro cell culture model (Caco-2) and those using an in situ perfused rat ileum model of the intestinal mucosa. Pharm. Res. 10:1710-1714 (1993).
5. Y. N. Wong, K. A. Holm, D. L. Burcham, S.-M. Huang, and C. Y. Quon. The pharmacokinetics and metabolism of DuP 532, a non-peptide angiotensin II receptor antagonist, in rats and dogs. Biopharm. Drug Disp. 15:53-63 (1994).
6. P. C. Wong, S.-M. Huang, R. J. Ardecky, D. J. Carini, A. T. Chiu, A. M. Agra, R. R. Wexler, and P. B. M. W. M. Timmermans. Pharmacology and pharmacokinetics of a novel nonpeptide angiotensin II receptor antagonist - DMP 811. Clin. and Exper. Hypertension. 17:1233-1256 (1995).
7. A. M. Agra and S.-M. Huang. Pharmacokinetics and bioavailability of DMP 811, an AII receptor antagonist, in animals-Effects of route of administration, dose, and salt form. Pharm. Res. 10:S342 (1993).
8. P. C. Wong, D. D. Christ, Y. N. Wong, and G. N. Lam. Nonpeptide angiotensin II receptor antagonist: Pharmacokinetics and pharmacodynamics of EXP3174, an active metabolite of losartan, in rats. Pharmacology (in press).
9. D. D. Christ, P. C. Wong, C. Y. Quon, Y. N. Wong, S. D. Hart, and G. N. Lam. The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK954) in the dog. J. Pharmacol. Exp. Ther. 268:1199-1205 (1994).
10. S.-M. Huang, A. M. Agra, D. L. Burcham, Y. N. Wong, and C. Y. Quon. Pharmacokinetics and bioavailability of DMP 581, an AII receptor antagonist, in animals - Effects of food and formulation. Pharm. Res. 10:S342 (1993).
11. M.-W. Lo, M. R. Goldberg, J. B. McCrea, H. Lu, C. I. Furtek, and T. D. Bjornsson. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin. Pharmacol. Ther. 58:641-649 (1995).
12. Y. N. Wong and P. C. Wong. Pharmacological and pharmacokinetic evaluation of EXP3312 (DuP 167), and orally active nonpeptide angiotensin II receptor antagonist. J. Pharm. Pharmacol. (submitted).
13. D. L. Burcham, B. J. Aungst, M. A. Hussain, M. A. Gorko, C. Y. Quon, and S.-M. Huang. The effect of absorption enhancers on the oral absorption of the GP IIb/IIIa receptor angatonist, DMP 728, in rats and dogs. Pharm. Res. 12 (1995).
14. F. L. S. Tse, T. M. Sanders, and J. P. Reo. Bioavailability of propranolol in the dog. Arch. Int. Pharmacodyn. 248:180-189 (1980).
15. A. Hayes and R. G. Cooper. Studies of the absorption, distribution and excretion of propranolol in rat, dog and monkey. J. Pharmacol. Exp. Ther. 176:302-311 (1971).
16. J. W. Paterson, M. E. Conolly, C. T. Dollery, A. Hayes, and R. G. Cooper. The pharmacodynamics and metabolism of propranolol in man. Pharmacol. Clin. 2:127-133 (1970).
17. D. A. Paterson, R. A. Conradi, R. Hilgers, T. J. Vidmar, and P. S. Burton. A non-aqueous partitioning system for predicting the oral absorption potential of peptides. Quant. Struct. Act. Relat. 13:4-10 (1994).
18. B. Testa, N. El Tayar, C. Altomare, P.-A. Carrupt, and R.-S. Tsai. Lipophilicity and hydrogen bonding capacity: Their role in drug binding and disposition. Proc. Int. Symp. Blood Binding Drug Transfer, Off Satell. 12th Int. Sym. Med. Chem. 1993, pp. 109-20.
19. W. D. Stein. The Movement of Molecules Across Cell Membranes, Academic Press, New York and London, 1967.
20. R. A. Conradi, A. R. Hilgers, N. F. H. Ho, and P. S. Burton. The influence of peptide structure on transport across Caco-2 cells I. Pharm. Res. 8:1453-1460 (1991).
21. R. A. Conradi, A. R. Hilgers, N. F. H. Ho, and P. S. Burton. The influence of peptide structure on transport across Caco-2 cells II. Peptide bond modification which results in improved permeability. Pharm. Res. 9:435-439 (1992).
22. D. E. Schmidt, J. R. Votaw, R. M. Kessler, and T. De Paulis. Aromatic and amine substituent effects on the apparent lipophilicities of N-[(2-pyrrolidinyl)methyl]-substituted benzamides. J. Pharm. Sci. 83:305-315 (1994).
23. M. J. S. Dewar, E. G. Zoebisch, E. F. Healy, and J. J. P. Stewart. AM1: A new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 107:3902-3909 (1985).
24. C. J. Cramer and D. G. Truhlar. An SCF solvation model for the hydrophobic effect and absolute free energies of solvation. Science 256:213-217 (1992).
25. C. J. Cramer, G. C. Lynch, G. D. Hawkins, D. G. Truhlar, and D. A. Liotard. AMSOL-version 4.0, QCPE Bulletin 13, 78 (1993), based in part on AMPAC-version 2.1 by D. A. Liotard, E. F. Healy, J. M. Ruiz, and M. J. S. Dewar.
26. L. Wesson and D. Eisenberg. Atomic solvation parameters applied to molecular dynamics of proteins in solution. Protein Sci. 1:227-235 (1992).
27. K. A. Sharp, A. Nicholls, R. Friedman, and B. Honig. Extracting hydrophobic free energies from experimental data: Relationship to protein folding and theoretical models. Biochemistry 30:9686-9697 (1991).
28. M. S. Karls, B. D. Rush, K. F. Wilkinson, T. J. Vidmar, P. S. Burton, and M. J. Ruwart. Desolvation energy: A major determinant of absorption, but not clearance, of peptides in rats. Pharm. Res. 8:1477-1481 (1991).